Abstract
We report the case of a 45-year-old woman diagnosed with non-Hodgkin lymphoma. Six months after completion of R-CHOP, she relapsed, and 2 cycles of R-ESHAP were given, with a view to allograft transplant. One month later, F-FDG PET/CT revealed disease progression. Biopsy of lymph nodes showed reactive changes, without evidence of lymphoma. Rituximab, a monoclonal antibody, is used for treatment of non-Hodgkin lymphoma, but its addition may result in an extensive inflammatory response. It is important to be aware of the potential for false-positive F-FDG PET/CT imaging after rituximab therapy. Unexpected findings should be confirmed by biopsy.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols
-
Cisplatin
-
Cytarabine
-
Etoposide
-
False Positive Reactions
-
Female
-
Fluorodeoxyglucose F18
-
Humans
-
Lymphoma, Non-Hodgkin / diagnostic imaging*
-
Lymphoma, Non-Hodgkin / drug therapy
-
Methylprednisolone
-
Middle Aged
-
Multimodal Imaging
-
Positron-Emission Tomography*
-
Radiopharmaceuticals
-
Rituximab / administration & dosage
-
Rituximab / adverse effects*
-
Rituximab / therapeutic use
-
Tomography, X-Ray Computed*
Substances
-
Antineoplastic Agents
-
Radiopharmaceuticals
-
Cytarabine
-
Fluorodeoxyglucose F18
-
Rituximab
-
Etoposide
-
Cisplatin
-
Methylprednisolone